Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers

NCT ID: NCT00113074

Last Updated: 2024-04-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

139 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop effective interventions that assist individuals with high blood pressure to quit smoking and prevent weight gain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

High blood pressure (BP), or hypertension, is a major risk factor for cardiovascular morbidity and mortality. Hypertension is associated with an elevated risk for several cardiovascular complications, including coronary heart disease, peripheral vascular disease, congestive heart failure, and stroke, as well as an increased risk for renal disease. Although there have been significant advances in the detection and treatment of high BP, approximately one in four adults in the United States is hypertensive. Cigarette smoking accounts for more than 400,000 premature deaths each year in this country alone, making it the leading cause of morbidity and mortality. Evidence from several epidemiological studies has demonstrated that, at any level of BP, smoking substantially increases the risk for all cardiovascular complications associated with hypertension. While cigarette smoking and hypertension both increase the risk of cardiovascular disease, these two risk factors act synergistically to produce a greater risk than their combined independent effects. Despite the considerable health risks, smoking among people with hypertension is very common, with a prevalence approaching that observed among those with normal BP. Unfortunately, although quitting smoking is especially important for patients with high BP, smoking cessation produces a nontrivial weight gain, averaging 5 kg, which may exacerbate hypertension in many patients with the disorder. Several studies have documented significant elevations in BP following smoking cessation, as well as increases in the prevalence of hypertension after quitting smoking. As such, it is important to develop effective interventions that assist in quitting smoking and preventing weight gain.

DESIGN NARRATIVE:

The objective of the trial is to recruit 750 smokers with Stage 1 hypertension or prehypertension (based on JNC VII criteria). The trial will provide all participants with a brief, validated, combined behavioral and pharmacologic smoking cessation intervention. Additionally, the study will randomly assign participants who are abstinent from smoking upon completing the cessation intervention to either a 12-week weight management and BP control program or self-help materials targeting lifestyle modification. The primary endpoint is change in BP among quit smokers at a one-year follow-up. Secondary endpoints include changes in body weight, dietary intake, urinary sodium excretion, physical activity, and relapse to smoking. Exploratory endpoints include changes in hypertensive status (e.g., movement from prehypertensive to hypertensive by JNC VII criteria) and changes in BP medication status. This is a multi-site clinical trial, with study locations in Rochester, Minnesota, and Iowa City, IA. The Rochester, MN site is currently closed for recruitment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases Heart Diseases Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Weight management and blood pressure control intervention

Group Type EXPERIMENTAL

Nicotine Replacement Therapy

Intervention Type DRUG

Nicotine replacement therapy program

Diet

Intervention Type BEHAVIORAL

Diet program

3

Self-help materials targeting lifestyle modification

Group Type ACTIVE_COMPARATOR

Nicotine Replacement Therapy

Intervention Type DRUG

Nicotine replacement therapy program

Diet

Intervention Type BEHAVIORAL

Diet program

2

Weight management intervention

Group Type EXPERIMENTAL

Nicotine Replacement Therapy

Intervention Type DRUG

Nicotine replacement therapy program

Diet

Intervention Type BEHAVIORAL

Diet program

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicotine Replacement Therapy

Nicotine replacement therapy program

Intervention Type DRUG

Diet

Diet program

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Smoke at least 5 cigarettes/day (or have quit within the last 6 weeks to enter the study for the weight gain prevention and BP control interventions)
* Pre-hypertensive or Stage I hypertension (systolic BP from 120 to 159 and/or diastolic BP from 80 to 99 mm Hg). Antihypertensive medications are not criteria for exclusion provided that BP is not over 160/100 mm Hg)
* Access to a telephone

Exclusion Criteria

* History of unstable cardiovascular disease, including myocardial infarction, stroke, and unstable angina within three months of study start
* Coronary artery bypass grafting or angioplasty/stent within three months of study start
* Cardiac dysrhythmia treated with anti-arrhythmia medication, except stable atrial fibrillation
* Untreated hyperthyroidism or pheochromocytoma
* History of congestive heart failure (NYHA Class III or IV)
* ECG evidence of 2nd or 3rd degree atrioventricular block
* Uncontrolled or Stage II Hypertension as defined as BP consistently above 160/100 mm Hg
* History of severe liver or kidney failure
* Current substance abuse (includes alcohol use in excess of 21 drinks a week)
* Presence of an unstable psychiatric condition
* Severe chronic obstructive pulmonary disease
* Symptomatic peripheral vascular disease
* Pulmonary hypertension with shortness of breath
* Congenital or valvular heart disease with shortness of breath
* Current use of a medication that may interfere with primary study endpoints or that may increase the risk of side effects from study medication that cannot be discontinued
* Pregnant or plans to become pregnant within the next year
* Planning to move out of the area or travel extensively during the intervention
* Any medical condition that would preclude any additional changes in diet
* Unable to further modify physical activity routine
* Cannot engage in moderate intensity exercise (e.g., walking)
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role collaborator

Mark Vander Weg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mark Vander Weg

Mark W. Vander Weg, PhD, University of Iowa

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark W. Vander Weg, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Iowa, Carver College of Medicine, Department of Internal Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Iowa, Carver College of Medicine, Department of Internal Medicine, Division of General Internal Medicine

Iowa City, Iowa, United States

Site Status

Mayo Clinic College of Medicine

Rochester, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Vander Weg MW, Klesges RC, Ebbert JO, Lichty EJ, DeBon M, North F, Schroeder DR, Dubbert PM. Trial design: blood pressure control and weight gain prevention in prehypertensive and hypertensive smokers: the treatment and prevention study. Contemp Clin Trials. 2008 Mar;29(2):281-92. doi: 10.1016/j.cct.2007.07.003. Epub 2007 Jul 19.

Reference Type BACKGROUND
PMID: 17716953 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01HL072782

Identifier Type: NIH

Identifier Source: secondary_id

View Link

200611724

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Behavioral Study to Control Blood Pressure
NCT01035554 COMPLETED PHASE2/PHASE3
Motivational Interviewing
NCT00208104 TERMINATED NA